Sean Sheridan and Zlatina Dobreva discuss the importance of licensing intellectual property in the life sciences industry in the successful commercialization of early-stage therapeutics. Different licensing structures reflect the need for licensors and licensees to consider the range of paths for early-stage biotechnology development and then take all available and mutually agreeable steps to protect their interests. Read the full piece below.
Drug price controls in the US: A roundtable discussion with experts
The United States is the world leader in innovative drug development, supporting patients and health systems globally by advancing the creation of new cures...